Skip Navigation
Menu Search
The Sidney Kimmel Comprehensive Cancer Center

In This Section      

News & Events

November 2018

Researchers at the Johns Hopkins Kimmel Cancer Center say they have added to evidence that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the early stages of cancer growth and spread but also uncover new treatment options that tumor genetic analysis alone may not.

October 2018

When Bill Johnson was diagnosed with an aggressive squamous cell carcinoma, specialists at Johns Hopkins Hospital, Suburban Hospital and the Johns Hopkins Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital worked together to provide him with the most effective treatment anywhere in the region. Thanks to this partnership, Mr. Johnson was able to participate in a clinical trial locally. Read more about Mr. Johnson's inspiring story, from the Fall 2018 issue of Johns Hopkins Medicine Suburban magazine.

April 2018

EVENT - CME Update on Melanoma and Non-Melanoma Skin Cancer

WHEN:  Wednesday, May 16
                6- 8 PM

WHERE: The Hotel at Arundel Preserve, Hanover, MD

FOR:    Dermatology, Family Practice, General Practice, Oncology

In the United States, the incidence of skin cancer is greater than that of all other cancers combined. Early diagnosis of melanoma and other aggressive skin cancers can be lifesaving. Skin cancer is a substantial public health concern and is being increasingly diagnosed and managed by primary care physicians. This activity aims to update physicians with new information on diagnosis and treatment of melanoma and non-melanoma skin cancer. This activity will consist of a buffet dinner followed by a series of brief lectures and case presentations.

Learn more and Register

March 2018

Dr. William Sharfman was elected to the Miller Coulson Academy of Clinical Excellence at Johns Hopkins.  The Academy honors outstanding clinicians who are teachers and mentors for young doctors, encouraging them to become caring, astute physicians.

January 2018

Dr. Suzanne Topalian was selected to receive the 16th Rosalind E. Franklin Award for Women in Science from the National Cancer Institute, NIH.

September 2017

melanoma program

Melanoma Program members participated in an annual 5K walk/run event sponsored by Moving for Melanoma of Delaware. Funds raised at this event were presented to the Program to support melanoma research at Hopkins, during an on-site visit in February 2018

October 2016

Dr. Suzanne Topalian received the 2016 Taubman Prize recognizing her contributions to translational cancer immunotherapy research and the development of immune checkpoint blocking drugs.  She shared the prize with Dr. Jedd Wolchok from Memorial Sloan-Kettering Cancer Center.

October 2016

Dr. William Sharfman was honored as the inaugural recipient of the Mary Jo Rogers Professorship in Cancer Immunology and Melanoma Research. Watch the dedication ceremony.

Johns Hopkins Melanoma Tumor Board Members of the Johns Hopkins Melanoma Program

September 2016

Members of the Johns Hopkins Melanoma Program participated in an annual 5K walk/run event sponsored by Moving for Melanoma of Delaware. Funds raised at this event were presented to the Program to support melanoma research at Hopkins, during an on-site visit in December.

melanoma Members of Moving for Melanoma of Delaware at Johns Hopkins Kimmel Cancer Center.

September 2015

Members of the Johns Hopkins Melanoma Program participated in an annual 5K walk/run event organized by Moving for Melanoma of Delaware. This event honors, supports and remembers patients with melanoma and their families.  Funds raised at this event were donated to the Melanoma Program to sponsor research in our clinics and laboratories

June 2015

Dr. Suzanne Topalian received the David A. Karnofsky Memorial Award and Lecture from the American Society of Clinical Oncology at their 51st Annual Meeting in Chicago, for her role in developing anti-PD-1 therapy. This award recognizes innovative clinical research and developments that have changed the way oncologists think about the general practice of oncology.

February 2015

Dr. Julie Lange has been accepted into the Miller-Coulson Academy of Clinical Excellence. She joins the exceptional clinicians who are committed to excellence in patient care.

March 2014

Dr. Suzanne L. Topalian, Dr. William H. Sharfman, Dr. Evan J. Lipson, Dr. Janis M. Taube, Dr. Drew M. Pardoll and colleagues describe overall survival, durable tumor regressions and long-term safety of nivolumab (anti-PD-1) in 107 patients with advanced melanoma. Nivolumab was well-tolerated, anti-tumor responses were durable and persisted after drug discontinuation, and overall survival rates compared favorably with those in previously published studies of similar patient populations.
Read more

Dr. Evan J. Lipson, Dr. William H. Sharfman and colleagues are the first to describe the successful administration of ipilimumab (Yervoy) to two kidney transplantation patients with metastatic melanoma.
Read more

February 2014

An article in The Washington Post titled, "New Therapies Raise Hope for a Breakthrough in Tackling Cancer," goes in depth discussing immunotherapies for melanoma.

December 2013

Latest PD1 Research featured in December's Issue of Nature

"Releasing the breaks - Tumors can put a brake on the immune system, but new therapies work by removing these brakes."
Read the latest cancer immunotherapy research by Suzanne Topalian, in the latest issue of Nature and Science.

"Breakthrough of the Year, Cancer Immunotherapy", Science Read article here

October 2013

Read the New York Times article titled, "Breaking through Cancer's Sheild", which examines studies at Johns Hopkins Kimmel Cancer Center that are using our bodies own immune system to fight and attack cancer cells.

June 2013

ASCO Interviews Dr. Suzanne Topalian on Anti-PD1

Dr. Suzanne Topalian talks to ecancer at the ASCO 2013 Annual Meeting about anti-PD1 results of a phase 1 study. This study looked at nivolumab to inhibit the immune checkpoint, PD1. The study reported substantial response in lung cancer and melanoma.

Dr. Suzanne Topalian discusses immune-based cancer therapies including anti-PD-1 in Tearing Down Cancer’s Walls (Johns Hopkins Health). See page 5.

December 2012

Read about the multidisciplinary teamwork behind the Johns Hopkins Melanoma Program in A Platform for Elevating Melanoma Clinical Research, from the Johns Hopkins Cutting Edge newsletter.

June 2012

Cancer Therapy That Boosts Immune System Ready For Wider Testing

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system’s ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer. More than 500 patients were treated in the studies of two drugs that target the same immune-suppressive pathway, and the investigators say there is enough evidence to support wider testing in larger groups of patients. The investigators say the treatment is safe, shrinks some tumors and a marker they identified may predict response.Read more.

April 2012

Johns Hopkins and Yale scientists have found that melanoma cells use a cloaking protein to hide from immune cells poised to attack the cancer. The work was published in the journal Science Translational Medicine. Read more.

February 2012

More Good News on Melanoma Drug

New studies on the FDA-approved drug vemurafenib show more progress in treating melanoma. Melanoma specialist Evan Lipson, M.D. comments on the study in the Cancer Matters blog.

December 2011

Melanoma Drug Among Top Trends in Cancer Research

Melanoma specialist Evan Lipson, M.D., cited the approval of the immune-based drug ipilumumab (Yervoy) as a major milestone in cancer treatment, not just for melanoma, but for cancer treatment in general, he says. There is likely much more to come from researchers seeking ways to use a patient's own immune system to attack cancer. Listen to Lipson's podcast on the Cancer Matters blog discussing this topic.

October 2011

A Johns Hopkins Children’s Center study of young people with melanoma, a deadly form of skin cancer, has found that some children have a higher risk of invasive disease than adults. The work was published in the journal Cancer.

August 2010

Tanning Beds and Melanoma Risk

Dr. Ginette Hinds discusses acral lentiginous melanoma, the most common form of melanoma in ethnic groups including African Americans, Asians, Pacific Islanders and Hispanics — groups conditioned to feel at very low risk for skin cancers --- in Johns Hopkins Medicine magazine’s “Skin Cancer’s Secret Life.” Read more.

January 2009

Johns Hopkins Melanoma Program in the New York Times

An article by Roger Martin, a patient with metastatic melanoma treated successfully at Johns Hopkins, appeared in the New York Times on January 4th. In this article, Mr. Martin writes about his care at Johns Hopkins and his experiences with this disease. His physician, Dr. William Sharfman, is the Clinical Co-Director for Oncology in the Hopkins Melanoma Program. For more information, read more.

Melanoma Expert Charles Balch Edits New Textbook

The fifth edition of the authoritative textbook Cutaneous Melanoma, edited by Dr. Charles Balch with other field experts, is now in print. Cutaneous Melanoma is a comprehensive treatise covering the epidemiology, prognosis, prevention, treatment, and biology of this disease. It serves as a reference for clinicians and scientific investigators worldwide. In addition to Dr. Balch, other contributors from the Hopkins Melanoma Program include Drs. Lieping Chen, Julie Lange, Lisa Jacobs, Joseph Califano, Nanette Liegeois, Richard Wahl, Anthony Tufaro, and Suzanne Topalian.

March 2009

Dr. Charles Balch discusses his co-authored book Cancer Guide: A Treatment and Facilities Guide for Patients and Their Families in the Johns Hopkins newsletter Dome.